Editor's Note The US Food & Drug Administration (FDA) has approved immunotherapy durvalumab for perioperative treatment of resectable non-small cell lung cancer (NSCLC), according to an August 15 announcement. The approval is for durvalumab (Imfinzi, AstraZeneca) in combination with platinum-based chemotherapy as a neoadjuvant treatment, followed by durvalumab alone as…

Read More

Editor's Note A post hoc analysis of the SCOT phase 3 randomized clinical trial reveals that initiating adjuvant chemotherapy more than 6 weeks after surgery is linked to worse disease-free survival (DFS) in patients with high-risk stage II and stage III colorectal cancer. Published June 12 in JAMA Surgery, the…

Read More

Editor's Note Medical professionals have long accepted that bilateral mastectomy does not improve survival outcomes for breast cancer patients. However, a study published in JAMA Oncology reveals a puzzling finding: Those who develop a second cancer in the other breast have a higher risk of death. As detailed in a…

Read More

Editor's Note A Massachusetts man, Marty Kedian, regained his voice after a pioneering larynx transplant at the Mayo Clinic in Arizona, The Associated Press (AP) reported July 9. According to the article, Kedian is only the third person in the U.S. to receive a total larynx transplant and the first…

Read More

Editor's Note A pair of immunotherapy drugs administered before surgery significantly diminished tumor size without serious safety concerns in patients with mismatch repair-deficient (dMMR) colorectal cancer, according to a study published in the New England Journal of Medicine. Healthline reported the news June 8. Constituting 10-15% of cases, dMMR cancer…

Read More

Editor's Note In esophageal cancer, combining preoperative and postoperative chemotherapy lead to better outcomes, fewer deaths, and higher likelihood of complete tumor regression than preoperative chemotherapy alone, according to a randomized clinical trial. US News and World Report reported the news June 4. Led by Dr. Jens Hoeppner from the…

Read More

Editor's Note A fluorescent marker dye that attaches to a protein specific to prostate cancer cells could help surgeons identify and remove them in real time, BBC News reported June 9. Developed by researchers from the University of Oxford in the UK, the dye reportedly performed promisingly in a trial…

Read More

Editor's Note Artificial intelligence (AI)-fueled analysis of electronic health records suggests that clinical guidelines for de-escalating surgery should be extended to younger breast cancer patients. Conducted by University of Pittsburgh and UPMC Hillman Cancer Center researchers and published in JCO Clinical Cancer Informatics, the analysis suggests that “surgery involving sentinel…

Read More

Editor's Note An AI model that outperformed MRI and ultrasound in identifying patients with axillary breast cancer metastasis shows the technology’s potential to reduce the need for needle or surgical biopsies, according to developers at UT Southwestern Medical Center. In a May 21 report on their new AI model, researchers…

Read More

Editor's Note Liver resection provides a significant survival benefit over percutaneous radiofrequency ablation (PRFA) or transarterial chemoembolization (TACE) in patients with early multinodular hepatocellular carcinoma (HCC), according to findings published May 15 in JAMA Surgery. Thus, liver resection should be considered the first therapeutic option in patients with early multinodular…

Read More